Compare Duke Energy Corp (DUK) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs 10X Genomics Inc — how do they compare? Duke Energy Corp trades at $116.65 (market cap $91.10B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: Duke Energy Corp is far larger — about 9× 10X Genomics Inc's market cap, and Duke Energy Corp pays a 3.71% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 74 Days and 10X Genomics Inc for 91 Days on average.
| DUK | TXG | |
|---|---|---|
Market Cap | $91.10B | $10.07B |
Volume | 4,199,050 | 5,657,286 |
Sector | Utilities | Health |
52-Week High | $133.46 | $97.74 |
52-Week Low | $113.23 | $11.48 |
Typical Hold Time | 74 Days | 91 Days |
Enterprise Value | $183.61B | $9.59B |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $116.84, up 1.16% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong fundamentals with a P/E of 17.6, net income margin of 15.78%, and robust cash flow from operations of $12.33B in 2025. Recent news highlights dividend declarations and data center growth opportunities, while analyst consensus is mixed with a $134.44 price target.
DUK offers a stable investment with reliable dividends and growth from data center demand, but faces risks from rising Treasury yields, high debt levels, and regulatory pressures. The stock's valuation is reasonable, and institutional interest remains positive, though technical indicators suggest near-term resistance at $118.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
